HRP20090571T1 - Pharmaceutical composition comprising cyclic somatostatin analogues - Google Patents
Pharmaceutical composition comprising cyclic somatostatin analoguesInfo
- Publication number
- HRP20090571T1 HRP20090571T1 HR20090571T HRP20090571T HRP20090571T1 HR P20090571 T1 HRP20090571 T1 HR P20090571T1 HR 20090571 T HR20090571 T HR 20090571T HR P20090571 T HRP20090571 T HR P20090571T HR P20090571 T1 HRP20090571 T1 HR P20090571T1
- Authority
- HR
- Croatia
- Prior art keywords
- ala
- pharmaceutical composition
- amino acid
- formula
- somatostatin analogues
- Prior art date
Links
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314695A GB0314695D0 (en) | 2003-06-24 | 2003-06-24 | Organic compounds |
| GB0325388A GB0325388D0 (en) | 2003-10-30 | 2003-10-30 | Organic compounds |
| PCT/EP2004/006794 WO2005000893A2 (en) | 2003-06-24 | 2004-06-23 | Pharmaceutical composition comprising cyclic somatostin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090571T1 true HRP20090571T1 (en) | 2009-11-30 |
Family
ID=33554159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090571T HRP20090571T1 (en) | 2003-06-24 | 2009-10-27 | Pharmaceutical composition comprising cyclic somatostatin analogues |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20070093412A1 (is) |
| EP (1) | EP1648934B1 (is) |
| JP (1) | JP4746541B2 (is) |
| KR (1) | KR101124136B1 (is) |
| AR (1) | AR044852A1 (is) |
| AT (1) | ATE438659T1 (is) |
| AU (1) | AU2004251866B2 (is) |
| BR (1) | BRPI0411820B8 (is) |
| CA (1) | CA2529449C (is) |
| CL (1) | CL2004001579A1 (is) |
| CO (1) | CO5650225A2 (is) |
| CY (1) | CY1109444T1 (is) |
| DE (1) | DE602004022420D1 (is) |
| DK (1) | DK1648934T3 (is) |
| EC (1) | ECSP056237A (is) |
| ES (1) | ES2328144T3 (is) |
| HK (1) | HK1089776A1 (is) |
| HR (1) | HRP20090571T1 (is) |
| IL (1) | IL172329A (is) |
| IS (1) | IS2705B (is) |
| MA (1) | MA27862A1 (is) |
| MX (1) | MXPA05013821A (is) |
| MY (1) | MY145375A (is) |
| NO (1) | NO330706B1 (is) |
| NZ (1) | NZ544157A (is) |
| PE (1) | PE20050285A1 (is) |
| PL (1) | PL1648934T3 (is) |
| PT (1) | PT1648934E (is) |
| RU (1) | RU2355418C2 (is) |
| SI (1) | SI1648934T1 (is) |
| TW (1) | TWI361194B (is) |
| WO (1) | WO2005000893A2 (is) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008329826B2 (en) | 2007-11-28 | 2013-01-17 | Novartis Ag | Use of somatostatin analogs in meningioma |
| CN101883785B (zh) * | 2007-12-03 | 2014-01-15 | 意大利法尔马科有限公司 | 新的非选择性生长抑素类似物 |
| FR2942227B1 (fr) * | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| CA2925651A1 (en) * | 2013-09-30 | 2015-04-02 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| CN104447962B (zh) * | 2014-12-29 | 2018-07-17 | 成都圣诺生物科技股份有限公司 | 一种合成帕瑞肽的方法 |
| GB201816637D0 (en) | 2018-10-12 | 2018-11-28 | Heptares Therapeutics Ltd | Selective somatostatin receptor agonists |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328214A (en) * | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| EP0083305B1 (de) * | 1981-12-24 | 1985-07-10 | Ciba-Geigy Ag | Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung |
| US4612366A (en) * | 1985-06-17 | 1986-09-16 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| JPH02111A (ja) * | 1987-08-03 | 1990-01-05 | Toyo Jozo Co Ltd | 経鼻投与用生理活性ペプチド製剤 |
| JP2641755B2 (ja) | 1988-01-29 | 1997-08-20 | 住友製薬株式会社 | コントロールリリース製剤 |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
| EP1099707A3 (en) | 1993-06-23 | 2002-01-09 | Diatide, Inc. | Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| ES2167189B1 (es) | 1999-12-17 | 2003-04-01 | Lipotec Sa | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| JP5721624B2 (ja) * | 2008-07-08 | 2015-05-20 | ノバルティス アーゲー | 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用 |
-
2004
- 2004-06-22 AR ARP040102163A patent/AR044852A1/es not_active Application Discontinuation
- 2004-06-22 PE PE2004000610A patent/PE20050285A1/es not_active Application Discontinuation
- 2004-06-23 AT AT04740213T patent/ATE438659T1/de active
- 2004-06-23 RU RU2006101720/15A patent/RU2355418C2/ru active Protection Beyond IP Right Term
- 2004-06-23 EP EP04740213A patent/EP1648934B1/en not_active Expired - Lifetime
- 2004-06-23 WO PCT/EP2004/006794 patent/WO2005000893A2/en active Search and Examination
- 2004-06-23 SI SI200431269T patent/SI1648934T1/sl unknown
- 2004-06-23 KR KR1020057024845A patent/KR101124136B1/ko active IP Right Grant
- 2004-06-23 MY MYPI20042450A patent/MY145375A/en unknown
- 2004-06-23 CL CL200401579A patent/CL2004001579A1/es unknown
- 2004-06-23 DE DE602004022420T patent/DE602004022420D1/de not_active Expired - Lifetime
- 2004-06-23 PL PL04740213T patent/PL1648934T3/pl unknown
- 2004-06-23 PT PT04740213T patent/PT1648934E/pt unknown
- 2004-06-23 CA CA2529449A patent/CA2529449C/en not_active Expired - Lifetime
- 2004-06-23 TW TW093118140A patent/TWI361194B/zh not_active IP Right Cessation
- 2004-06-23 AU AU2004251866A patent/AU2004251866B2/en active Active
- 2004-06-23 MX MXPA05013821A patent/MXPA05013821A/es active IP Right Grant
- 2004-06-23 NZ NZ544157A patent/NZ544157A/en not_active IP Right Cessation
- 2004-06-23 DK DK04740213T patent/DK1648934T3/da active
- 2004-06-23 US US10/560,751 patent/US20070093412A1/en not_active Abandoned
- 2004-06-23 ES ES04740213T patent/ES2328144T3/es not_active Expired - Lifetime
- 2004-06-23 BR BRPI0411820A patent/BRPI0411820B8/pt active IP Right Grant
- 2004-06-23 JP JP2006516037A patent/JP4746541B2/ja not_active Expired - Lifetime
-
2005
- 2005-12-01 IL IL172329A patent/IL172329A/en active IP Right Grant
- 2005-12-19 EC EC2005006237A patent/ECSP056237A/es unknown
- 2005-12-21 MA MA28680A patent/MA27862A1/fr unknown
- 2005-12-27 CO CO05130258A patent/CO5650225A2/es not_active Application Discontinuation
-
2006
- 2006-01-20 IS IS8247A patent/IS2705B/is unknown
- 2006-01-24 NO NO20060375A patent/NO330706B1/no unknown
- 2006-09-08 HK HK06110030.5A patent/HK1089776A1/xx not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/359,527 patent/US8299209B2/en active Active
- 2009-09-30 CY CY20091101022T patent/CY1109444T1/el unknown
- 2009-10-27 HR HR20090571T patent/HRP20090571T1/xx unknown
-
2012
- 2012-09-27 US US13/628,900 patent/US20130035286A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090571T1 (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
| BR9609335B8 (pt) | Análogos de somatostatina, bem como composição farmacêutica compreendendo os mesmos. | |
| WO1994012219A3 (en) | Modified insulin-like growth factors | |
| HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
| EP0340741A3 (en) | Polyethylene glycol derivatives, modified peptides and production thereof | |
| NO20071369L (no) | Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv | |
| DK1660528T3 (da) | Mutein af tåre-lipocalin | |
| MXPA06001283A (es) | Derivados de insulina novedosos. | |
| ATE402957T1 (de) | Analoge des menschlichen interferon-alpha mit niedriger toxizität | |
| ATE367398T1 (de) | Verfahren zur rückfaltung von proteinen mit freien cysteinresten | |
| HUP0300684A2 (hu) | Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| KR900002801A (ko) | 당뇨병 치료용 약학적제제 | |
| DE60031999D1 (de) | Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend polypeptide | |
| IL175319A0 (en) | Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof | |
| RU2006120484A (ru) | Микрочастицы, содержащие аналоги соматостатина | |
| EA200000378A1 (ru) | Усеченные по амино-концу мср-2 как антагонисты хемокинов | |
| WO2007135117A3 (en) | Soluble, stable insulin-containing formulations | |
| DE3780000D1 (de) | Peptidverbindungen. | |
| MY147920A (en) | Antibacterial and antiviral peptides from actinomadura namibiensis | |
| WO2005004899A3 (de) | Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen | |
| HUP0301396A2 (hu) | Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk | |
| ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
| ATE481980T1 (de) | Verfahren zur verabreichung eines thymosin-alpha 1 peptids | |
| DK1506295T3 (da) | Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf |